| Pharmaceutical Information |
| Drug Name |
Flibanserin |
| Drug ID |
BADD_D00904 |
| Description |
Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. |
| Indications and Usage |
For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. |
| Marketing Status |
approved; investigational |
| ATC Code |
G02CX02 |
| DrugBank ID |
DB04908
|
| KEGG ID |
D02577
|
| MeSH ID |
C098107
|
| PubChem ID |
6918248
|
| TTD Drug ID |
D0S9CB
|
| NDC Product Code |
73223-006; 58604-214 |
| UNII |
37JK4STR6Z
|
| Synonyms |
flibanserin | 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one | BIMT 17 | BIMT-17 | Addyi |
|
| Chemical Information |
| Molecular Formula |
C20H21F3N4O |
| CAS Registry Number |
167933-07-5 |
| SMILES |
C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
